MedTrace Logo

Synbiotic Supplementation and Inflammation in Predialysis Chronic Kidney Disease

NCT07430280 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-02-27

No results posted yet for this study

Summary

Chronic kidney disease (CKD) is a long-term condition in which the kidneys gradually lose their ability to function properly. People with chronic kidney disease (CKD) often experience chronic inflammation and digestive symptoms that may affect their quality of life.

This study aims to evaluate whether daily supplementation with a synbiotic (a combination of probiotics and prebiotics) can reduce inflammation and improve gastrointestinal symptoms in adults with chronic kidney disease (CKD) stages 3 to 5 who are not receiving dialysis.

Participants will be randomly assigned to receive either a synbiotic containing Lactobacillus rhamnosus, Bifidobacterium longum, and agave fructans, or a placebo, for a total of 16 weeks. Blood tests will be performed to measure inflammation, and participants will complete questionnaires related to digestive symptoms, quality of life, and dietary habits.

The information obtained from this study may help improve nutritional strategies and supportive care for people living with chronic kidney disease.

Conditions

Interventions

DIETARY_SUPPLEMENT

Synbiotic Supplement

Oral synbiotic supplement administered once daily for 16 weeks.

OTHER

Placebo

Placebo identical in appearance, taste, and administration to the synbiotic supplement, administered once daily for 16 weeks.

Sponsors & Collaborators

  • Centenario Hospital Miguel Hidalgo

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-01
Primary Completion
2026-03-01
Completion
2026-06-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07430280 on ClinicalTrials.gov